Stockreport

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Genelux Corporation  (GNLX) 
PDF – Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated [Read more]